Pre-dosing with lilotomab prior to therapy with (177)Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients

PURPOSE: (177)Lu-lilotomab satetraxetan is a novel anti-CD37 antibody radionuclide conjugate for the treatment of non-Hodgkin lymphoma (NHL). Four arms with different combinations of pre-dosing and pre-treatment have been investigated in a first-in-human phase 1/2a study for relapsed CD37+ indolent...

Descripción completa

Detalles Bibliográficos
Autores principales: Stokke, Caroline, Blakkisrud, Johan, Løndalen, Ayca, Dahle, Jostein, Martinsen, Anne C. T., Holte, Harald, Kolstad, Arne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953993/
https://www.ncbi.nlm.nih.gov/pubmed/29470615
http://dx.doi.org/10.1007/s00259-018-3964-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953993/
https://www.ncbi.nlm.nih.gov/pubmed/29470615
http://dx.doi.org/10.1007/s00259-018-3964-9

Ejemplares similares